Replies to post #260 on KalVista Pharmaceuticals (KALV)

[Global Interface]

There will be a conference call next week. Here's to hoping they have a good explanation.

On the surface, this deal looks very fishy...

Currently, CBYL is nothing more than $40m and a ticker.

How is KV "purchasing shares" such that they will own 80% and we are then $40m with a weak preclinical pipeline that will quickly draw down that cash?

I'm missing something, right?